SLNO
Soleno Therapeutics Inc
$
67.160
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
69.595
Open
69.530
VWAP
67.76
Vol
1.14M
Mkt Cap
3.57B
Low
66.750
Amount
77.16M
EV/EBITDA(TTM)
--
Total Shares
36.86M
EV
3.33B
EV/OCF(TTM)
--
P/S(TTM)
--
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
0.347
-136.49%
--
--
0.215
-116.93%
--
--
0.058
-103.14%
Estimates Revision
The market is revising Upward the revenue expectations for Soleno Therapeutics, Inc. (SLNO) for FY2025, with the revenue forecasts being adjusted by 22.39% over the past three months. During the same period, the stock price has changed by -20.16%.
Revenue Estimates for FY2025
Revise Upward
+22.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-60.24%
In Past 3 Month
Stock Price
Go Down
-20.16%
In Past 3 Month
11 Analyst Rating
Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 119.82 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 67.160
Low
106.00
Averages
119.82
High
145.00
Current: 67.160
Low
106.00
Averages
119.82
High
145.00
Wells Fargo
Overweight
maintain
$123
2025-09-24
Reason
Wells Fargo
Price Target
$123
2025-09-24
maintain
Overweight
Reason
Wells Fargo believes Acadia Pharmaceuticals' (ACAD) Phase 3 failure removes a near-term competitor to Soleno Therapeutics' (SLNO) VYKAT XR. Wells thinks Soleno's shares should trade up at least 20% on Acadia Pharmaceuticals' failure in PWS, Prader-Willi syndrome. The firm remains bullish on VYKAT's launch and would be a buyer at these levels into Q3 print. Wells has an Overweight rating on Soleno with a price target of $123 on the shares.
Wells Fargo
Overweight
initiated
$123
2025-08-20
Reason
Wells Fargo
Price Target
$123
2025-08-20
initiated
Overweight
Reason
Wells Fargo initiated coverage of Soleno Therapeutics with an Overweight rating and $123 price target. The shares are down 23% this month on concerns over Vykat's satiety, competition and and its recent financing which could be a sign of no near-term takeover, the analyst tells investors in a research note. Wells views the concerns as overblown. Vykat's launch in Prader-Willi syndrome remains early, and the significant unmet should drive meaningful near-term uptake, the analyst tells investors in a research note. Wells recommends buying Soleno shares on the recent pullback.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$100 -> $110
2025-08-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$100 -> $110
2025-08-18
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Soleno Therapeutics to $110 from $100 and keeps a Buy rating on the shares. The firm says Citizen Petitions usually do not result in withdrawals of products from the U.S. market, as over 80% of those filed since 2001 have been denied or failed to elicit a response from the FDA. It updated the company's model post the Q2 report.
Oppenheimer
Oppenheimer
Outperform
maintain
$105 -> $110
2025-08-07
Reason
Oppenheimer
Oppenheimer
Price Target
$105 -> $110
2025-08-07
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Soleno Therapeutics to $110 from $105 and keeps an Outperform rating on the shares. The firm notes Vykat XR sales of $32.7M in its first launch quarter came in line with last month's pre-announcement. With a U.S. launch trending toward cash-flow positive and EU sales poised to begin next year, Oppenheimer views Soleno as a highly attractive, clean growth story.
TD Cowen
Buy
maintain
$115 -> $120
2025-08-07
Reason
TD Cowen
Price Target
$115 -> $120
2025-08-07
maintain
Buy
Reason
TD Cowen raised the firm's price target on Soleno Therapeutics to $120 from $115 and keeps a Buy rating on the shares. The firm notes Soleno reported impressive Vykat XR revenue of $33M in its first partial quarter and reiterated the 646 PSFs and 295 unique prescribers as of 6/30. Payor support is also proving strong, with a third of insured U.S. lives already covered. TD Cowen remains confident in Vykat XR's strong value proposition for the PWS community as well as this team's ability to continue executing on this launch.
Baird
Brian Skorney
Outperform
maintain
$105 -> $121
2025-07-11
Reason
Baird
Brian Skorney
Price Target
$105 -> $121
2025-07-11
maintain
Outperform
Reason
Baird analyst Brian Skorney raised the firm's price target on Soleno Therapeutics to $121 from $105 and keeps an Outperform rating on the shares. The firm updated its model after Q2 Vykat sales blew out expectations.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Soleno Therapeutics Inc (SLNO.O) is 51.87, compared to its 5-year average forward P/E of -5.45. For a more detailed relative valuation and DCF analysis to assess Soleno Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.45
Current PE
51.87
Overvalued PE
13.56
Undervalued PE
-24.47
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.73
Current EV/EBITDA
31.33
Overvalued EV/EBITDA
5.29
Undervalued EV/EBITDA
-3.83
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
74.25
Current PS
67.16
Overvalued PS
305.09
Undervalued PS
-156.59
Financials
Annual
Quarterly
FY2025Q2
32.66M
Total Revenue
FY2025Q2
YoY :
-76.65%
-5.42M
Operating Profit
FY2025Q2
YoY :
-78.46%
-4.71M
Net Income after Tax
FY2025Q2
YoY :
-84.21%
-0.09
EPS - Diluted
FY2025Q2
YoY :
-28.55%
-12.62M
Free Cash Flow
FY2025Q2
97.87
Gross Profit Margin - %
FY2025Q2
-14.42
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1314.42% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
339.4K
USD
2
6-9
Months
199.8M
USD
12
0-12
Months
1.7M
USD
8
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.9M
Volume
5
0-12
Months
2.0M
Volume
4
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
443.3K
Volume
Months
0-12
8
19.4M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 1314.42% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
339.4K
USD
2
6-9
Months
199.8M
USD
12
0-12
Months
1.7M
USD
8
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SLNO News & Events
Events Timeline
2025-10-21 (ET)
2025-10-21
10:52:22
STAT's Feuerstein Calls Soleno's Lack of Q3 Sales Preannouncement 'Disappointing'
2025-10-16 (ET)
2025-10-16
13:43:53
Betaville alert brings attention to Soleno Therapeutics rumor
2025-10-13 (ET)
2025-10-13
08:13:17
Hahn Joins the Board of Directors at Soleno Therapeutics
Sign Up For More Events
Sign Up For More Events
News
7.0
10-27GlobenewswireSLNO Investor Update: Contact The Rosen Law Firm If You've Experienced Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO) to Learn About Your Rights
7.0
10-20PRnewswireRosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
7.0
10-18PRnewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
Sign Up For More News
People Also Watch
UTZ
UTZ Brands Inc
10.530
USD
+0.86%
TRUP
Trupanion Inc
39.990
USD
-1.21%
LBTYA
Liberty Global Ltd
11.000
USD
+0.27%
GTX
Garrett Motion Inc
16.940
USD
+0.53%
CNTA
Centessa Pharmaceuticals PLC
24.900
USD
+2.34%
MESO
Mesoblast Ltd
16.660
USD
+1.40%
NPWR
NET Power Inc
3.820
USD
-3.78%
WNS
WNS (Holdings) Ltd
0
USD
+0.10%
ARDT
Ardent Health Inc
14.560
USD
-0.14%
TSLX
Sixth Street Specialty Lending Inc
22.620
USD
+0.22%
FAQ
What is Soleno Therapeutics Inc (SLNO) stock price today?
The current price of SLNO is 67.16 USD — it has decreased -3.06 % in the last trading day.
What is Soleno Therapeutics Inc (SLNO)'s business?
What is the price predicton of SLNO Stock?
What is Soleno Therapeutics Inc (SLNO)'s revenue for the last quarter?
What is Soleno Therapeutics Inc (SLNO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Soleno Therapeutics Inc (SLNO)'s fundamentals?
How many employees does Soleno Therapeutics Inc (SLNO). have?